Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation

Robert W. Ricketts, Nirbhay N. Singh, Cynthia R. Ellis, Sharee Chambers, Yadhu N. Singh, Sharon J. Carmanico, Victor Vadney, John C. Cooke

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tardive dyskinesia (TD) is one of the major problems associated with the long-term use of neuroleptic medication in individuals with mental retardation. Although no satisfactory treatment is currently available for TD, there has been a suggestion in the research literature that, in theory, calcium channel blockers and vitamin E may be effective in reducing the symptoms of TD. We assessed the effects of verapamil, a calcium channel blocker, and vitamin E on TD in seven adults with mental retardation in a double-blind, placebo-controlled, cross-over study. Following an open baseline, each subject received placebo, verapamil (80 mg/qid), and vitamin E (400 IU/tid) in random order, with each phase lasting 8 weeks. The subjects were rated on the Abnormal Involuntary Movement Scale (AIMS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS) by trained raters. The maintenance medication for all subjects was kept constant during the course of the study. Results showed that although some subjects had a reduction in their TD ratings neither verapamil nor vitamin E produced clinically or statistically significant changes when compared to placebo and baseline conditions. However, the changes associated with vitamin E were promising enough to warrant further investigation of this agent in the treatment of TD in individuals with mental retardation.

Original languageEnglish (US)
Pages (from-to)161-174
Number of pages14
JournalJournal of Developmental and Physical Disabilities
Volume7
Issue number2
DOIs
StatePublished - Jun 1 1995

Fingerprint

Calcium Channel Blockers
Vitamin E
Intellectual Disability
Verapamil
Placebos
Antipsychotic Agents
Dyskinesias
Identification (control systems)
Cross-Over Studies
Tardive Dyskinesia
Maintenance
Therapeutics
Research

Keywords

  • calcium channel blockers
  • mental retardation
  • tardive dyskinesia
  • verapamil
  • vitamin E

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Developmental and Educational Psychology

Cite this

Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation. / Ricketts, Robert W.; Singh, Nirbhay N.; Ellis, Cynthia R.; Chambers, Sharee; Singh, Yadhu N.; Carmanico, Sharon J.; Vadney, Victor; Cooke, John C.

In: Journal of Developmental and Physical Disabilities, Vol. 7, No. 2, 01.06.1995, p. 161-174.

Research output: Contribution to journalArticle

Ricketts, Robert W. ; Singh, Nirbhay N. ; Ellis, Cynthia R. ; Chambers, Sharee ; Singh, Yadhu N. ; Carmanico, Sharon J. ; Vadney, Victor ; Cooke, John C. / Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation. In: Journal of Developmental and Physical Disabilities. 1995 ; Vol. 7, No. 2. pp. 161-174.
@article{deb450f24a9d4cdb825f6d796139b992,
title = "Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation",
abstract = "Tardive dyskinesia (TD) is one of the major problems associated with the long-term use of neuroleptic medication in individuals with mental retardation. Although no satisfactory treatment is currently available for TD, there has been a suggestion in the research literature that, in theory, calcium channel blockers and vitamin E may be effective in reducing the symptoms of TD. We assessed the effects of verapamil, a calcium channel blocker, and vitamin E on TD in seven adults with mental retardation in a double-blind, placebo-controlled, cross-over study. Following an open baseline, each subject received placebo, verapamil (80 mg/qid), and vitamin E (400 IU/tid) in random order, with each phase lasting 8 weeks. The subjects were rated on the Abnormal Involuntary Movement Scale (AIMS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS) by trained raters. The maintenance medication for all subjects was kept constant during the course of the study. Results showed that although some subjects had a reduction in their TD ratings neither verapamil nor vitamin E produced clinically or statistically significant changes when compared to placebo and baseline conditions. However, the changes associated with vitamin E were promising enough to warrant further investigation of this agent in the treatment of TD in individuals with mental retardation.",
keywords = "calcium channel blockers, mental retardation, tardive dyskinesia, verapamil, vitamin E",
author = "Ricketts, {Robert W.} and Singh, {Nirbhay N.} and Ellis, {Cynthia R.} and Sharee Chambers and Singh, {Yadhu N.} and Carmanico, {Sharon J.} and Victor Vadney and Cooke, {John C.}",
year = "1995",
month = "6",
day = "1",
doi = "10.1007/BF02684961",
language = "English (US)",
volume = "7",
pages = "161--174",
journal = "Journal of Developmental and Physical Disabilities",
issn = "1056-263X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation

AU - Ricketts, Robert W.

AU - Singh, Nirbhay N.

AU - Ellis, Cynthia R.

AU - Chambers, Sharee

AU - Singh, Yadhu N.

AU - Carmanico, Sharon J.

AU - Vadney, Victor

AU - Cooke, John C.

PY - 1995/6/1

Y1 - 1995/6/1

N2 - Tardive dyskinesia (TD) is one of the major problems associated with the long-term use of neuroleptic medication in individuals with mental retardation. Although no satisfactory treatment is currently available for TD, there has been a suggestion in the research literature that, in theory, calcium channel blockers and vitamin E may be effective in reducing the symptoms of TD. We assessed the effects of verapamil, a calcium channel blocker, and vitamin E on TD in seven adults with mental retardation in a double-blind, placebo-controlled, cross-over study. Following an open baseline, each subject received placebo, verapamil (80 mg/qid), and vitamin E (400 IU/tid) in random order, with each phase lasting 8 weeks. The subjects were rated on the Abnormal Involuntary Movement Scale (AIMS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS) by trained raters. The maintenance medication for all subjects was kept constant during the course of the study. Results showed that although some subjects had a reduction in their TD ratings neither verapamil nor vitamin E produced clinically or statistically significant changes when compared to placebo and baseline conditions. However, the changes associated with vitamin E were promising enough to warrant further investigation of this agent in the treatment of TD in individuals with mental retardation.

AB - Tardive dyskinesia (TD) is one of the major problems associated with the long-term use of neuroleptic medication in individuals with mental retardation. Although no satisfactory treatment is currently available for TD, there has been a suggestion in the research literature that, in theory, calcium channel blockers and vitamin E may be effective in reducing the symptoms of TD. We assessed the effects of verapamil, a calcium channel blocker, and vitamin E on TD in seven adults with mental retardation in a double-blind, placebo-controlled, cross-over study. Following an open baseline, each subject received placebo, verapamil (80 mg/qid), and vitamin E (400 IU/tid) in random order, with each phase lasting 8 weeks. The subjects were rated on the Abnormal Involuntary Movement Scale (AIMS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS) by trained raters. The maintenance medication for all subjects was kept constant during the course of the study. Results showed that although some subjects had a reduction in their TD ratings neither verapamil nor vitamin E produced clinically or statistically significant changes when compared to placebo and baseline conditions. However, the changes associated with vitamin E were promising enough to warrant further investigation of this agent in the treatment of TD in individuals with mental retardation.

KW - calcium channel blockers

KW - mental retardation

KW - tardive dyskinesia

KW - verapamil

KW - vitamin E

UR - http://www.scopus.com/inward/record.url?scp=51649133459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649133459&partnerID=8YFLogxK

U2 - 10.1007/BF02684961

DO - 10.1007/BF02684961

M3 - Article

AN - SCOPUS:51649133459

VL - 7

SP - 161

EP - 174

JO - Journal of Developmental and Physical Disabilities

JF - Journal of Developmental and Physical Disabilities

SN - 1056-263X

IS - 2

ER -